The estimated Net Worth of Tran Nguyen is at least $3.62 Million dollars as of 17 May 2023. Mr. Nguyen owns over 95,000 units of Prothena plc stock worth over $2,055,326 and over the last 12 years he sold PRTA stock worth over $0. In addition, he makes $1,566,460 as Chief Financial Officer and Chief Operating Officer at Prothena plc.
Tran has made over 13 trades of the Prothena plc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 95,000 units of PRTA stock worth $2,484,250 on 17 May 2023.
The largest trade he's ever made was exercising 95,000 units of Prothena plc stock on 17 May 2023 worth over $2,484,250. On average, Tran trades about 8,974 units every 106 days since 2013. As of 17 May 2023 he still owns at least 98,200 units of Prothena plc stock.
You can see the complete history of Mr. Nguyen stock trades at the bottom of the page.
Tran B. Nguyen serves as Chief Financial Officer, Chief Operating Officer of the Company. Prior to joining Prothena in 2013, he was Vice President, Chief Financial Officer (from 2010 to 2011) and then Senior Vice President, Chief Financial Officer of Somaxon Pharmaceuticals, Inc. (a biopharmaceutical company), from 2011 until its sale in 2013. Mr. Nguyen was Vice President, Chief Financial Officer at Metabasis Therapeutics, Inc. (a biopharmaceutical company) from 2009 until its sale in 2010. From 2007 to 2009, he was a Vice President in the Healthcare Investment Banking group at Citi Global Markets, Inc., and from 2004 to 2007 he served in various capacities as a healthcare investment banker at Lehman Brothers, Inc. Mr. Nguyen serves on the board of directors of Sierra Oncology, Inc. (a publicly-traded clinical-stage oncology company) and Rain Therapeutics Inc. (a privately-held clinical-stage oncology company). He earned his BA in Economics and Psychology from Claremont McKenna College and his MBA from the Anderson School of Management at the University of California, Los Angeles.
As the Chief Financial Officer and Chief Operating Officer of Prothena plc, the total compensation of Tran Nguyen at Prothena plc is $1,566,460. There are 3 executives at Prothena plc getting paid more, with Wagner Zago having the highest compensation of $3,341,640.
Tran Nguyen is 46, he's been the Chief Financial Officer and Chief Operating Officer of Prothena plc since 2018. There are 19 older and 4 younger executives at Prothena plc. The oldest executive at Prothena Corporation plc is Christopher Henney, 78, who is the Independent Director.
Tran's mailing address filed with the SEC is C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Over the last 12 years, insiders at Prothena plc have traded over $79,429,035 worth of Prothena plc stock and bought 2,987,732 units worth $75,619,043 . The most active insiders traders include Capital, Llc Eco R1, Co Plc Elan Corp Plc Elan S..., and Helen Susan Kim. On average, Prothena plc executives and independent directors trade stock every 21 days with the average trade being worth of $946,769. The most recent stock trade was executed by Karin L Walker on 24 January 2024, trading 5,000 units of PRTA stock currently worth $67,650.
prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f
Prothena plc executives and other stock owners filed with the SEC include: